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Abstract
Background: Cytokine flow cytometry (CFC) provides a multiparameter alternative to ELISPOT
assays for rapid quantitation of antigen-specific T cells. To increase the throughput of CFC assays,
we have optimized methods for stimulating, staining, and acquiring whole blood or PBMC samples
in 96-well or 24-well plates.
Results: We have developed a protocol for whole blood stimulation and processing in deep-well
24- or 96-well plates, and fresh or cryopreserved peripheral blood mononuclear cell (PBMC)
stimulation and processing in conventional 96-well round-bottom plates. Samples from both HIV-
1-seronegative and HIV-1-seropositive donors were tested. We show that the percent response,
staining intensity, and cell recovery are comparable to stimulation and processing in tubes using
traditional methods. We also show the equivalence of automated gating templates to manual gating
for CFC data analysis.
Conclusion: When combined with flow cytometry analysis using an automated plate loader and
an automated analysis algorithm, these plate-based methods provide a higher throughput platform
for CFC, as well as reducing operator-induced variability. These factors will be important for
processing the numbers of samples required in large clinical trials, and for epitope mapping of
patient responses.
Background
Cytokine flow cytometry (CFC) assays use short-term in
vitro  stimulation and intracellular cytokine staining to
quantitate potentially rare populations of antigen-specific
T cells (see [1,2] for reviews). Because of the multi-para-
metric readout of flow cytometry, CFC is an attractive
alternative to ELISPOT assays, allowing the dissection of
responses by various phenotypes of T cells [3,4]. However,
ELISPOT assays have traditionally been more amenable to
high-throughput analysis due to their plate-based nature
and the availability of automated instrumentation to ana-
lyze ELISPOT plates.
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In order to provide similar advantages to the CFC plat-
form, we optimized the ability to stimulate, process, and
acquire CFC samples in 96-well or 24-well plates, using
stimulation with the superantigen Staphylococcal entero-
toxin B (SEB), as well as cytomegalovirus (CMV) or HIV
antigens. The result was two protocols optimized for stim-
ulation and processing of whole blood samples (in deep-
well 24- or 96-well plates), and one protocol optimized
for stimulation and processing of PBMC samples (in con-
ventional round-bottom 96-well plates). These optimized
protocols compared favorably with tube-based methods,
and, when combined with automated acquisition and
analysis software, resulted in a rapid and highly standard-
ized assay with greatly reduced hands-on time.
Results and Discussion
Comparison of CFC responses in tubes and plates
Both whole blood and PBMC samples are frequently used
for CFC assays. While conditions need to be optimized for
these two sample types [5–8], comparable results can be
obtained between whole blood and PBMC stimulations
[9]. We therefore optimized protocols for each sample
type. Processing of whole blood requires lysis of erythro-
cytes, so deep-well plates were employed to allow for
addition of the required volume of lysis buffer. Whole
blood samples from HIV-1-seropositive donors can
potentially have lowered CD4+ T cell counts, so 24-well
deep-well plates were used. These can accommodate up to
1 ml of blood per sample, plus up to 9 ml of lysis buffer.
A representative comparison for each type of assay is
shown in Figure 1. Whole blood (200 µl per sample) was
stimulated in conical-bottom 96-well deep-well plates.
PBMC (106 cells in 200 µl) were stimulated in conven-
tional round-bottom 96-well plates. Finally, whole blood
(1 ml per sample) from an HIV-1-seropositive donor was
stimulated in round-bottom 24-well deep-well plates.
Each sample was stimulated for 6 hours in the presence or
absence of a CMV pp65 or HIV-1 Gag p55 peptide mix-
ture. Replicate samples for each assay type were incubated
in parallel in 15-ml conical polypropylene tubes, using a
standard CFC protocol [5,6]. As seen in Figure 1, the plate
and tube assays give qualitatively and quantitatively simi-
lar results.
In order to more accurately quantify the percentage of
antigen-specific T cells identified by plate-based versus
tube-based assays, a larger number of donors were tested
by each method used in Figure 1. The results (Figure 2)
show a close correlation between tube- and plate-based
assays for the percentage of cytokine-producing cells.
Strong correlations were seen for both SEB and CMV or
HIV peptide stimulation, and in both CD4 and CD8-gated
T cells. The slope of the linear regression lines approxi-
mated 1, indicating no particular bias toward higher
results in either tubes or plates.
Comparison of staining intensity in tubes and plates
Next, we compared the mean fluorescence intensity of
cytokine staining in tube-based versus plate-based assays,
using the same samples as above. As seen in Figure 3, the
staining intensity for IFNγ compared favorably between
tubes and plates, with plates yielding similar or even
higher fluorescence intensities than tubes. This was true
for both whole blood (deep-well) and PBMC (shallow-
well) assays. The differences in the ratio of tube-to-plate
staining intensity could be related to staining volume,
which is a function of the residual volume after aspiration.
This volume tends to be lowest in shallow-well 96-well
plates (using our multichannel aspiration manifolds),
and highest in 24-well plates.
Effect of overnight resting on cryopreserved PBMC
For cryopreserved PBMC, we tested the effect of an incu-
bation period after thawing but before antigen stimula-
tion in 96-well plates. While we had previously reported
that such a "rest" period did not significantly affect the
result (percent of cytokine-positive cells) [10], we now
show that it does affect the fluorescence intensity of
cytokine-positive cells. As shown in Figure 4, we found
that IFNγ staining intensity was significantly increased
after an overnight incubation of thawed cells in medium,
prior to stimulation with CMV pp65 peptide mix. This
increased cytokine staining intensity correlated with an
increase in functional avidity as measured by responses to
lower concentrations of peptide antigen in titration exper-
iments (data not shown).
Comparison of cell recovery in tubes and plates
We also compared cell recoveries in tube- versus plate-
based assays. Cell loss in CFC assays is likely to be associ-
ated with centrifugation and washing. By using a 12-chan-
nel vacuum manifold with custom-length prongs (see
Methods), we were able to aspirate supernatants after cen-
trifugation in a rapid and reproducible manner, without
risk of aspirating the cell pellets. As such, cell recoveries
for both PBMC and whole blood were similar in plates
and tubes (Figure 5). For PBMC, recoveries in plates
appeared to be slightly better than in tubes, perhaps
because of the need to incubate PBMC tubes on a slant
[7], and associated difficulties with recovering adherent
cells from the side of the tube. Also, in the tube protocol,
cells are transferred from a 15-ml stimulation tube to 5-ml
staining tubes, which may account for some cell loss.
While 5-ml polystyrene tubes can be used for stimulation,
they result in reduced cell recovery and slightly reduced
activation efficiency with protein antigens (our unpub-
lished data). The plate protocol has the advantage thatBMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/9
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cells are stimulated, processed, and acquired in a single
plate.
Automated gating algorithm
In addition to errors that may have been introduced by
differential washing, another frequent source of variation
in CFC assays is analysis. Relatively minor differences in
gating can quantitatively affect the results [2], and the
prospect of subjectivity in gating is a concern for many
investigators. Analysis also tends to be time-consuming
using most conventional software packages. However,
using software that contains a cluster-finding algorithm,
we were able to build templates for automated CFC gating
that identify the required cell populations and report a
percentage of CD69-positive, cytokine-positive cells. Sam-
ples could then be processed by these templates using
batch analysis, and results automatically exported to a
spreadsheet. By using the cluster-finding algorithm, much
of the subjectivity in gating is avoided.
An example of such a template is shown in Figure 6A.
When compared to expert manual gating, the automated
template of Figure 6A yielded highly correlated results for
a set of 25 whole blood samples stimulated with CMV
pp65 peptide mix or SEB (Figure 6B).
The template of Figure 6A also yielded good correlation
with manual gating for a set of 39 HIV-1-seropositive
Representative examples of tube- and plate-based CFC results Figure 1
Representative examples of tube- and plate-based CFC results. (A) Whole blood from a CMV seropositive donor was stimu-
lated (or not) with CMV pp65 peptide mix in 15 ml conical polypropylene tubes (top panels) or a deep-well 96-well polypropyl-
ene plate (bottom panels). (B) PBMC from another CMV seropositive donor were stimulated as above in 15 ml conical 
polypropylene tubes (top panels) or a 96-well round-bottom tissue culture plate (bottom panels). (C) Whole blood from an 
HIV-seropositve donor was stimulated (or not) with HIV p55 gag peptide mix in 15 ml conical polypropylene tubes (top panels) 
or a deep-well 24-well round-bottom polypropylene plate (bottom panels). Backgrounds and response to peptide mix were 
essentially equivalent in tubes and plates in each case. All data are gated on CD3+CD8+ cells.
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whole blood samples stimulated with CMV pp65 peptide
mix, HIV p55 peptide mix, or SEB (Figure 7A). However,
it was noted that for some CD4+ responses in the HIV-1-
seropositive dataset, the automated template under-
counted IFNγ+ cells relative to manual gating, resulting in
a slope of slightly less than 1 for the linear regression line
(Figure 7A, CMV pp65 and SEB responses). In particular,
samples with very few CD4+ T cells tended to result in
undercounting of IFNγ+ cells by the automated template,
due to suboptimal CD4+ cluster identification. Such sam-
ples were better analyzed using a template that created a
fixed region for CD3+CD4+  gating, tethered to the
CD3+CD4- population (Figure 7B). This fixed region was
set to avoid the exclusion of CD4dim cells when the total
number of CD4+ cells was very low. When this revised
template was applied to the determination of CD4+
responses for the HIV-1-seropositive dataset, the resulting
linear regressions yielded higher slopes, very close to 1
(Figure 7C). Thus, changes in the gating scheme
employed by the automated template can improve the
quality of data generated under certain circumstances. In
particular, samples containing very few CD4+ cells may be
best handled by the modified template of Figure 7B.
Another alternative to the template of Figure 6A that was
advantageous in certain circumstances involved changing
the initial gating of lymphocytes. Datasets containing
poorly defined lymphocyte clusters were best gated by
Correlation of tube- and plate-based CFC assays Figure 2
Correlation of tube- and plate-based CFC assays. Stimulation vessels and antigens were as in Figure 1. (A) Correlation of whole 
blood CMV and SEB responses in 17 CMV seropositive donors, done in tubes versus deep-well 96-well conical polypropylene 
plates. (B) Correlation of PBMC CMV and SEB responses in 13 CMV seropositive donors, done in tubes versus 96-well round-
bottom tissue culture plates. (C) Correlation of whole blood HIV and SEB responses in 10 HIV seropositive donors, done in 
tubes versus deep-well 24-well round-bottom polypropylene plates.
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using an initial automated region to identify CD3+ lym-
phocytes in a CD3 versus side scatter plot, rather than
using forward versus side scatter gating (data not shown).
The key features of any of these automated templates
include: (a) the ability to track populations that "roam" as
a result of donor, reagent, or instrument variations; (b)
the ability to create a maximally sized region that will
include activated T cells that have partially down-modu-
lated the marker in question (CD3, CD4, and/or CD8);
and (c) the ability to tether a manually drawn region to
another population cluster to allow identification of
potentially rare populations of cells (i.e., cytokine-posi-
tive cells).
Gains in assay throughput and standardization
As a result of applying the above methodology, the
throughput of CFC assays is increased in a manner pro-
portional to the number of samples per experiment. For
example, a complete plate of 96 samples can be processed
with significantly less time than an equivalent number of
tubes (saving perhaps 1–2 hours of pipetting time). Since
acquisition on a plate loader can be unsupervised, this
saves an additional 3–5 hours of technician time. Finally,
batch analysis with an automated template might save at
least one more hour of technician time as compared to
manual analysis.
The other major benefit of the methodology described
here is standardization. The more rapid sample handling
associated with plate-based methods would be expected
to reduce sample-to-sample differences in incubation
Mean fluorescence intensity of IFNγ staining using tube- or plate-based CFC Figure 3
Mean fluorescence intensity of IFNγ staining using tube- or plate-based CFC. Data are taken from the samples of Figure 2. 
Error bars represent SEM.
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Effect of overnight "resting" on cryopreserved PBMC Figure 4
Effect of overnight "resting" on cryopreserved PBMC. (A) Representative comparison of fresh PBMC, cryopreserved PBMC, 
and cryopreserved PBMC incubated overnight prior to stimulation (all from the same CMV+ donor). Unstimulated samples 
(top row) and CMV pp65 peptide mix-stimulated samples (bottom row) show similar results, but the IFNγ fluorescence inten-
sity (MFI) is greatest in the cells rested overnight prior to stimulation. (B) Results of triplicate samples stimulated with CMV 
pp65 peptide mix and analyzed for percentage of IFNγ+ cells or IFNγ mean fluorescence intensity. Error bars represent SEM. 
All data were gated on CD3+CD4- cells. Similar results were obtained for TNFα+ cells (not shown). Results are representative 
of two similar experiments.
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times for each processing step. Thus, variability in results
associated with these time differences should also be
reduced. Perhaps more significantly, automated analysis
using a standard template should standardize differences
in gating that occur between users. It is known that gating
differences can make relatively large contributions to
result variability [2]. In particular, the exclusion of cells
with down-modulation of CD4 or CD8 staining due to
activation can negatively impact the accurate reporting of
cytokine-positive cells. The automated templates
described above have been engineered to include these
down-modulated cells in a reproducible fashion.
Comparison to ELISPOT assays
By providing plate compatibility and a degree of automa-
tion to CFC assays, they become attractive relative to com-
peting platforms such as ELISPOT. These two assays both
measure cytokine production, but CFC can provide multi-
parameter information that clearly distinguishes T cell
subsets such as CD4 and CD8 as well as a number of other
phenotypic markers on the responding cells. While ELIS-
POT assays have been reported to have lower limits of
detection than CFC assays [11], CFC generally reports
higher numbers of positive cells [9,12–14]. Thus, plate-
based CFC assays can provide the benefits of multiparam-
eter information, with higher efficiency of detection and
comparable throughput to ELISPOT assays.
Conclusions
We conclude that CFC assays can be performed with
increased throughput using plate-based methodology. By
optimizing the type of plate used for either PBMC or
Cell recovery in tube- and plate-based CFC assays Figure 5
Cell recovery in tube- and plate-based CFC assays. Recovery was calculated by addition of a known number of beads to each 
CFC sample at the end of sample processing. Data are shown as a percentage of cells counted in fresh whole blood or PBMC 
from the same donor. Error bars represent SEM of 3 donors for each assay.
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Automated gating of CFC samples Figure 6
Automated gating of CFC samples. (A) Example of automated gating. A cluster-finding algorithm is employed to automatically 
identify small lymphocytes in forward versus side scatter (R1, top left panel; this region can also be drawn manually during sam-
ple acquisition). A similar automated region is calculated for CD3+CD8- and CD3+CD8+ lymphocytes (R2 and R3, top right 
panel). R2 and R3 are set for maximal size to allow inclusion of activated cells that have down-modulated CD3 and CD8 (bold 
dots). The lower left plot, gated on regions R1 and R2 (CD3+CD8- lymphocytes), uses the cluster-finding algorithm to identify 
the CD69-IFNγ- population (R4). This population is tethered to a rectangular region that identifies the CD69+IFNγ+ cells (R5). 
The lower left plot is similar, but gated on R1 and R3 (CD3+CD8+ lymphocytes). The percentage of gated events in R5 is 
reported. (B) Correlation of the automated gating template to expert manual gating. Whole blood from 23 CMV seropositive 
donors was stimulated in deep-well 96-well plates, then analyzed manually or using the automated template in (A). Using a 
batch analysis protocol, many CFC samples can be analyzed and the resulting data downloaded to a spreadsheet in a rapid 
fashion.
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Automated gating of HIV-1-seropositive CFC samples Figure 7
Automated gating of HIV-1-seropositive CFC samples. (A) Correlation of automated gating to expert manual gating. Whole 
blood from 39 HIV-1-seropositive donors was stimulated using the antigens shown, then analyzed manually or with the auto-
mated template of Figure 6A. (B) Revised template designed for samples with very low numbers of CD4+ cells. A fixed region 
for CD3+CD4+ cells (R3) has been created and tethered to the automated region R2. (C) Improved performance of the 
revised template for calculating CD4+ responses from the dataset of (A). Note that the slope of the linear regression line for 
pp65 peptide mix and SEB stimulation is now closer to 1.
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whole blood, we are able to activate, process, and acquire
samples in a single plate. This avoids labor and cell loss
associated with sample transfers. We also show that data
analysis can be streamlined using an automated template
that uses cluster-finding algorithms. The data generated
from such semi-automated plate-based assays are equiva-
lent to data generated using tube-based methods and
manual analysis. In addition, these plate-based methods
and automated analysis templates are expected to increase
standardization of CFC, such as would be required for its
use in large clinical trials. Other applications include
epitope mapping using a matrix of overlapping peptide
pools [15], where high throughput and an array format
are desirable features.
Methods
For additional details of procedures and notes on critical
parameters, please see reference [16].
Stimulation reagents
SEB (Sigma Chemical Co., St. Louis, MO) was dissolved in
sterile PBS at 0.5 mg/ml and stored at 4°C. It was used at
a final concentration of 1 µg/ml of blood or PBMC sus-
pension. CMV pp65 and HIV p55 gag peptide mixes (15
amino acid residues in length, overlapping by 11 amino
acid residues each) have been described previously [10].
They were stored in small aliquots at -80°C, and diluted
in sterile PBS on the day of use to achieve a final concen-
tration of approximately 2 µg/ml/peptide. In some
experiments, costimulatory antibodies to CD28 and
CD49d (FastImmune, BD Biosciences, San Jose, CA) were
added at a final concentration of 1 µg/ml each [8]. Brefel-
din A (FastImmune or Sigma) was stored in small aliquots
at -20°C and diluted in sterile PBS on the day of use to
achieve a final concentration of 10 µg/ml.
Plates and accessories
Whole blood was activated in deep-well polypropylene
plates, using 96-well plates (BD Discovery Labware, Bed-
ford, MA; or E&K Scientific, Campbell, CA) for 200 µl
samples, or 24-well plates (Qiagen, Hilden, Germany) for
up to 1 ml samples. PBMC were activated in standard 96-
well round-bottom polystyrene tissue culture plates (Fal-
con, BD Discovery Labware). 12-channel vacuum mani-
folds with 7 mm prongs (for standard plates) or 35 mm
prongs (for deep-well plates) were purchased from V&P
Scientific, San Diego, CA. Centrifuge holders compatible
with deep-well plates were purchased from Sorvall Instru-
ments, Newtown, CT.
Collection and cryopreservation of PBMC
Informed consent (approved by either the UCSF or the BD
Biosciences Institutional Review Board) was provided by
all volunteer blood donors. For PBMC preparation, whole
blood was collected in Cell Preparation Tubes (CPT™)
containing sodium heparin (BD Vacutainer, Franklin
Lakes, NJ). PBMC were isolated following the manufac-
turer's instructions, and washed with RPMI-1640 medium
containing 10% heat-inactivated fetal bovine serum and
antibiotic/antimycotic solution (cRPMI-10, all compo-
nents from Sigma). Fresh PBMC were resuspended in a
volume of cRPMI-10 equivalent to the original blood vol-
ume. In some experiments, PBMC were resuspended for
cryopreservation at 2 × 107 cells/ml in RPMI-1640+12.5%
human serum albumin (Sigma). An equal volume of cold
RPMI-1640 medium+10% human serum albumin+20%
dimethyl sulfoxide (Sigma) was slowly added. Cells were
transferred to freezing vials (1 ml/vial) and placed at -
80°C in a freezing container (Mr. Frosty, Nunc, Naper-
ville, IL). Cryopreserved cells were thawed briefly in a
37°C water bath, then 1 ml of warm (37°C) cRPMI-10
medium was added dropwise to the vial, and the cell sus-
pension transferred to a 50 ml conical polypropylene tube
(Falcon) containing 8 ml of warm cRPMI-10 medium.
The cells were centrifuged for 7 minutes at 250 × G, then
resuspended in cRPMI-10 at 5 × 106 cells/ml.
CFC of tube-based specimens
For comparison to plate assays, heparinized whole blood
or PBMC in cRPMI-10 were activated in 15 ml conical
polypropylene tubes (Falcon) and processed in 12 × 75
mm round-bottom polystyrene tubes (Falcon). A stand-
ard method, previously described [5,6], was followed.
Cell activation in plates
200 µl of heparinized whole blood or PBMC in cRPMI-10
medium were plated per well in 96-well plates; 0.5 ml or
1 ml of whole blood was plated per well in 24-well plates.
Cryopreserved PBMC were then rested at 37°C overnight,
while fresh PBMC or whole blood samples were activated
immediately. Activation reagents as described above were
prepared in a master mix to allow their combined addi-
tion to each well in a volume of 20 µl per 200 µl of cell
suspension. The cells were incubated at 37°C for 6 hours.
In some experiments, the plates were then held overnight
at 18°C, using a programmable water bath.
Cell processing in plates
20 µl of 20 mM EDTA were added per 200 µl of cell sus-
pension, and incubated for 15 minutes at room tempera-
ture, followed by vigorous pipetting to dislodge adherent
cells. For PBMC, the plates were then centrifuged at 250 ×
G for 5 minutes, and supernatants aspirated using a vac-
uum manifold (V&P Scientific, see above). Cells were
resuspended in 100 µl/well of FACS Lysing Solution (BD
Biosciences). For whole blood, 8–10 volumes of FACS
Lysing Solution were added directly to the EDTA-treated
blood. For both PBMC and whole blood, cells were incu-
bated in FACS Lysing Solution for 10 minutes at room
temperature, then centrifuged for 5 minutes at 500 × G.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/9
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Supernatants were aspirated using an appropriate-length
vacuum manifold (described above). Cells were resus-
pended in FACS Permeabilizing Solution 2 (BD Bio-
sciences) (200 µl for PBMC; 1 ml for deep-well 96-well
plates; 2 ml for 24-well plates). After an additional 10
minute incubation at room temperature, sample wells of
deep-well plates were filled with wash buffer (PBS+0.5%
bovine serum albumin+0.1% NaN3) and all plates were
centrifuged for 5 minutes at 500 × g. Supernatants were
aspirated as above, and the cells washed a second time.
PBMC plates were subjected to a third wash, then all
samples were resuspended in 20 µl of antibody cocktail
containing anti-IFNγ FITC/CD69 PE/CD4 or CD8 PerCP-
Cy5.5/CD3 APC (FastImmune, BD Biosciences). In exper-
iments of Figure 7, CD4 PE-Cy5 (Beckman Coulter,
Miami, FL) was used in place of CD4 PerCP-Cy5.5. Sam-
ples were incubated for 60 minutes at room temperature
in the dark, then washed twice as above before resuspend-
ing in a final volume of 200 µl of 1% paraformaldehyde
in PBS (250 µl for 24-well plates).
Flow cytometric analysis
Samples were acquired within 24 h of staining using a
FACSCalibur flow cytometer and CellQuest Pro software
(BD Biosciences). Plate-based samples were acquired on
the FACSCalibur using a Multiwell Autosampler and Mul-
tiwell Plate Manager software (BD Biosciences). In gen-
eral, 40,000 CD4+ or CD8+ events were collected. For
plate-based samples, sample volume was set to 200 µl and
mixing volume to 100 µl in Multiwell Plate Manager.
Acquisition criteria were set to 40,000 events of interest
(CD3+CD4+ or CD3+CD8+ lymphocytes), or 180 seconds.
Manual analysis was done in CellQuest Pro or FloJo soft-
ware (Tree Star, Inc., San Carlos, CA)  by gating on both
small lymphocytes and CD3+CD4+ (or CD3+CD8+) cells.
A gated dot plot displaying CD69 versus IFNγ from an
SEB-stimulated sample was then used to set a "response
region" around double-positive cells. This response
region was then applied to all samples to determine the
percentage of cytokine-positive cells. Automated analysis
was done as described in Figure 6A or 7B, using "Snap-to"
gating and tethered region tools in CellQuest Pro 5.0.1.
Determination of cell recovery
The absolute counts of CD3+ T cells in whole blood and
PBMC were determined using TruCOUNT Control beads
and TriTest CD4 FITC/CD8 PE/CD3 PerCP antibody cock-
tail (BD Biosciences). For the samples representing 100%
cell recovery, 50 µl of uncultured whole blood or PBMC
were aliquoted by reverse pipetting into 12 × 75 mm pol-
ystyrene tubes containing 20 µl of TriTest CD4 FITC/CD8
PE/CD3 PerCP. Each cell sample was stained in triplicate.
The samples were mixed well and incubated for 30 min-
utes at room temperature in the dark, and then lysed/fixed
using 450 µl of FACS Lysing Solution. After a 15-minute
incubation at room temperature, 50 µl of TruCOUNT
"Low" or "Medium" beads were added by reverse pipet-
ting. The samples were mixed well and acquired immedi-
ately using a FACSCalibur flow cytometer.
CFC samples were also stained in triplicate. EDTA-treated
activated whole blood in deep-well plates and tubes (200
µl) or 24-well plates (1000 µl) and PBMC in shallow-well
plates and tubes (200 µl) were lysed/fixed and permeabi-
lized as described above. The samples were stained with
20 µl of TriTest CD4 FITC/CD8 PE/CD3 PerCP for 30
minutes at room temperature in the dark, washed twice
and resuspended for acquisition in 200 µl of wash buffer.
TruCOUNT "Low" or "Medium" beads were then added
by reverse pipetting at 50 µl per sample. The samples were
mixed well and acquired immediately.
Samples were acquired on a FACSCalibur flow cytometer
using an FL3 (for CD3 PerCP) threshold. The CD3+ lym-
phocytes were identified in FL3 vs SSC and region R1 was
drawn to include all CD3+  cells. The acquisition was
carried out until 10,000 CD3+ events were collected, how-
ever, all events passing the FL3 threshold were stored in
order to include the beads, which were then identified
and gated (R2) in FL1 vs FL2. The absolute numbers of
CD3+ lymphocytes were calculated as follows: (# of events
in R1)/(# of events in R2) × (# of beads per test)/(test
volume).
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